scispace - formally typeset
Journal ArticleDOI

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

TLDR
The improvement in overall survival establishes the combination of dabrafenib and trametinib as the standard targeted treatment for BRAF Val600 mutation-positive melanoma.
About
This article is published in The Lancet.The article was published on 2015-08-01. It has received 1099 citations till now. The article focuses on the topics: Dabrafenib & Trametinib.

read more

Citations
More filters
Posted ContentDOI

Mi-2β-targeted inhibition induces immunotherapy response in melanoma

TL;DR: A Mi-2β-targeted inhibitor Z36-MP5 was developed, which specifically and effectively induced a response to immune checkpoint blockades in otherwise resistant melanomas, and highlights a viable strategy to improve immunotherapies in melanoma.
Journal ArticleDOI

Long-term control of melanoma brain metastases with co-occurring intracranial infection and involuntary drug reduction during COVID-19 pandemic: A case report

TL;DR: Long-term control of melanoma brain metastases with co-occurring intracranial infection and involuntary drug reduction during COVID-19 pandemic was studied in this paper.
Journal ArticleDOI

Current Trends in Mucosal Melanomas: An Overview

TL;DR: In this paper , the authors provide an updated overview about molecular features, clinical advancements and therapeutic directions of the primary mucosal melanoma which represents a rare and heterogeneous malignancy characterized by a poor prognosis.
References
More filters
Journal ArticleDOI

A multiple testing procedure for clinical trials.

TL;DR: The overall size of the procedure is shown to be controlled with virtually the same accuracy as the single sample chi-square test based on N(m1 + m2) observations and the power is found to bevirtually the same.
Related Papers (5)